- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Video
Future Directions in the Treatment of Atopic Dermatitis
Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, talk about how clinical approaches and understanding of risk/benefit profiles are evolving in light of the emerging long-term data.
Andrew F. Alexis, MD, MPH: Are there any other take-home messages that you have from this paper, Ben?
Benjamin N. Lockshin, MD: That was well said by you. I want to take that as a snippet and leave with that. Regarding this article, I truly believe that when discussing with patients the risks and benefits from alternative agents, we need to go past the primary end points and the early safety data and think about things in the long haul. This addresses that. This is a nice marriage. It’s almost a union between real-world data and clinical trial data.
Andrew F. Alexis, MD, MPH: Thank you. Well, time flies. That was a great discussion, Ben. I want to thank formally thank Dr Lockshin for joining me in this discussion. I truly hope that you, the viewer, enjoyed this episode of [Dermatology Times®] Between the Lines journal club experience. Thank you for tuning in. I hope to see you next time.
Transcript edited for clarity
